{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-188088","form_type":"8-K","ticker":"OLPX","cik":"0001868726","company_name":"OLAPLEX HOLDINGS, INC.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.459977+00:00","generated_at":"2026-05-17T10:01:05.976320+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Olaplex acquires biotech firm Purvala Bioscience for $10.5M in cash","bullets":["Purchase price $10.5M, subject to adjustments; $1.05M escrowed for 15 months for indemnification.","Purvala is a Boston biotech founded by MIT professor Dr. Bradley Olsen, focused on bioinspired molecules for health/beauty.","This is Olaplex's first acquisition since its launch over 10 years ago, signaling renewed innovation push.","Olaplex CEO Amanda Baldwin said Purvala tech could create 'next generation of disruptive science-backed product innovation'."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-188088","json":"https://secwatch.observer/filing/0001193125-25-188088.json","markdown":"https://secwatch.observer/filing/0001193125-25-188088.md","text":"https://secwatch.observer/filing/0001193125-25-188088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868726/000119312525188088/0001193125-25-188088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868726/000119312525188088/d70869d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:01:05.976320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}